Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...

Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.

Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than ...

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Eli Lilly and Company said Wednesday they plan to build new pharmaceutical manufacturing sites in the United States.

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...

Eli Lilly (NYSE:LLY) shares soar, driven by strong growth in weight-loss drugs, major investments, and bullish analyst ratings.

Eli Lilly is unleashing new ammunition in its fight against cheaper, compounded versions of its obesity blockbuster Zepbound.

Oklahoma Attorney General Gentner Drummond Office on Wednesday confirmed action is in order with the Food and Drug Administration (FDA) addressing counterfeit weight-loss drug makers.